Medical and Surgical Complications of Inflammatory Bowel Disease in the Elderly: A Systematic Review

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1132-1140

  Shung, Dennis L ^a   Abraham, Bincy ^b   Sellin, Joseph ^a   Hou, Jason K ^a,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d HSRandD Houston Center of Excellence   (United States)

Author keywords

Complications; Crohn s disease; Elderly; Postoperative complications; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ABDOMINAL SURGERY; ADVERSE EFFECTS; AGE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HOSPITALIZATION; HUMAN; MORTALITY; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84937965938     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3462-2     Document Type: Review

References (46)

1. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.
2. Robertson DJ, Grimm IS. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 2001;30:409–426.
3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46.e42–54.e42 (quiz e30).
4. Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19:355–363.
5. Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterol Hepatol. 2008;4:337–347.
6. Vavricka SR, Rogler G. Treatment of severe ulcerative colitis: differences in elderly patients? Dig Dis Basel Switz. 2009;27:315–321.
7. Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy of inflammatory bowel disease in the elderly—prospects and complications. J Crohns Colitis. 2011;5:177–188.
8. Swaroop PP. Inflammatory bowel diseases in the elderly. Clin Geriatr Med. 2007;23:809–821, vi.
9. Picco MF, Cangemi JR. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 2009;38:447–462.
10. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–1897.
11. Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm Bowel Dis. 2013;19:2257–2272.
12. Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–877.
13. Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn’s disease. Aliment Pharmacol Ther. 2005;21:1211–1216.
14. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–3140.
15. Morgacheva O, Furst DE. Use of MTX in the elderly and in patients with compromised renal function. Clin Exp Rheumatol. 2010;28:S85–S94.
16. Sergi G, De Rui M, Sarti S, et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28:509–518.
17. Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58:1791–1796.
18. Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238:221–228.
19. Harper PC, McAuliffe TL, Beeken WL. Crohn’s disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med. 1986;146:753–755.
20. Feagins LA, Spechler SJ. Biologic agent use varies inversely with age at diagnosis in Crohn’s disease. Dig Dis Sci. 2010;55:3164–3170.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
22. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:30–35.
23. Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol. 1997;92:461–464.
24. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:789–795.
25. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–189.
26. Ananthakrishnan AN, McGinley EL, Binion DG, et al. Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:176–182.
27. Navaneethan U, Parasa S, Venkatesh PGK, et al. Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2011;5:189–195.
28. Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003;186:514–518.
29. Triantafillidis JK, Emmanouilidis A, Pomonis E, et al. Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. J Gastroenterol. 2001;36:312–316.
30. Ha CY, Newberry RD, Stone CD, et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8:682-e1–687.e1.
31. Almogy G, Sachar DB, Bodian CA, et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg Chic Ill. 1960;2001:1396–1400.
32. Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch Surg Chic Ill. 1960. 2005;140:534–539 (discussion 539–540).
33. Ho KS, Chang CC, Baig MK, et al. Ileal pouch anal anastomosis for ulcerative colitis is feasible for septuagenarians. Colorectal Dis Off J Assoc Coloproctol G B Irel. 2006;8:235–238.
34. Bauer JJ, Gorfine SR, Gelernt IM, et al. Restorative proctocolectomy in patients older than fifty years. Dis Colon Rectum. 1997;40:562–565.
35. Tremaine WJ, Timmons LJ, Loftus EV Jr, et al. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther. 2007;25:1435–1441.
36. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–2415.
37. Walmsley RS, Gillen CD, Allan RN. Prognosis and management of Crohn’s disease in the over-55 age group. Postgrad Med J. 1997;73:225–229.
38. Grimm IS, Friedman LS. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 1990;19:361–389.
39. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57:121–126.
40. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42:1017–1025.
41. Olivier P, Bertrand L, Tubery M, et al. Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey. Drugs Aging. 2009;26:475–482.
42. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc. 1996;44:194–197.
43. Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4:36–41.
44. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract Off J World Inst Pain. 2008;8:287–313.
45. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109:212–223.
46. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409–1422.